Shilpa Medicare

What does Shilpa Medicare do?

Shilpa Medicare Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology industry, incorporated in 1987, with recent quarterly net sales of 331 Cr and net profit of 15 Cr as of March 2025. The company has a market cap of Rs 8,963 Cr and key financial metrics include a P/E ratio of 84.00 and a debt-equity ratio of 0.24.

Overview: <BR>Shilpa Medicare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History: <BR>Shilpa Medicare Limited was incorporated in 1987 and transitioned from a Private Limited Company to a Public Limited Company in 1993. The company underwent a name change to Shilpa Medicare Limited in 2003. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 331 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 15 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 8,963 Cr (Mid Cap)<BR><BR>Key Metrics: <BR>P/E: 84.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.24 <BR>Return on Equity: 4.42% <BR>Price to Book: 3.73 <BR><BR>Contact Details: <BR>Address: #12-6-214/A1, Hyderabad Road Raichur Karnataka : 584135 <BR>Tel: 91-8532-238704 <BR>Email: info@vbshilpa.com <BR>Website: http://www.vbshilpa.com

Has Shilpa Medicare declared dividend?

Yes, Shilpa Medicare Ltd has declared a 110% dividend, amounting to ₹1.1 per share, with an ex-date of September 19, 2022. Despite this, the dividend yield is 0%, as total returns have primarily come from significant price appreciation over various periods.

Shilpa Medicare Ltd has declared a 110% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 110%<BR>- Amount per share: 1.1<BR>- Ex-date: 19 Sep 22<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 6.35%, with no dividend return, resulting in a total return of 6.35%.<BR><BR>Over the past year, the price return was 72.64%, and there was no dividend return, leading to a total return of 72.64%.<BR><BR>In the 2-year period, the price return was 296.75%, with no dividend return, resulting in a total return of 296.75%.<BR><BR>For the 3-year period, the price return was 115.56%, with a dividend return of 0.26%, culminating in a total return of 115.82%.<BR><BR>In the 4-year period, the price return was 62.17%, with a dividend return of 0.39%, resulting in a total return of 62.56%.<BR><BR>Over the last 5 years, the price return was 95.73%, with a dividend return of 0.47%, leading to a total return of 96.2%.<BR><BR>Overall, Shilpa Medicare has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price appreciation, particularly over longer time frames, despite the minimal contribution from dividends.

Who are the peers of the Shilpa Medicare?

Shilpa Medicare's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Pharma, Strides Pharma, FDC, SPARC, and Supriya Lifesci. While Shilpa Medicare has average management risk and below-average growth, it achieved a 1-year return of 81.93%, outperforming peers like Aarti Pharma and SPARC.

Peers: The peers of Shilpa Medicare are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Aarti Pharma, Strides Pharma, FDC, SPARC, and Supriya Lifesci.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Shilpa Medicare, Aarti Pharma, FDC, and the rest. Growth is excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while below average growth is noted at Divi's Lab., Torrent Pharma, Shilpa Medicare, Aarti Pharma, Strides Pharma, FDC, SPARC, and the rest. Excellent capital structure is seen in Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Aarti Pharma, and FDC, while below average capital structure is found at Shilpa Medicare, Strides Pharma, SPARC, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Aarti Pharma at 58.00%, while the lowest is SPARC at -7.64%. Shilpa Medicare's 1-year return of 81.93% is significantly higher than both. Additionally, the peers with negative six-month returns include Torrent Pharma, Strides Pharma, and SPARC.

Who are in the management team of Shilpa Medicare?

As of March 2023, the management team of Shilpa Medicare includes Omprakash Inani (Chairman), Vishnukant Bhutada (Managing Director), Sharath Reddy Kalakota (Whole-time Director), and several independent directors: Arvind Vasudeva, Hetal Gandhi, Kamal K Sharma, and Anita Bandyopadhyay, along with Ritu Tiwary as Company Secretary. This team oversees the company's operations and strategic direction.

As of March 2023, the management team of Shilpa Medicare includes the following individuals:<BR><BR>1. Omprakash Inani - Chairman (Non-Executive)<BR>2. Vishnukant Bhutada - Managing Director<BR>3. Sharath Reddy Kalakota - Whole-time Director<BR>4. Arvind Vasudeva - Independent Director<BR>5. Hetal Gandhi - Independent Director<BR>6. Ritu Tiwary - Company Secretary & Compliance Officer<BR>7. Kamal K Sharma - Independent Director<BR>8. Anita Bandyopadhyay - Independent Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Who are the top shareholders of the Shilpa Medicare?

The top shareholders of Shilpa Medicare include promoter Vishnukant Chaturbhuj Bhutada with 6.51%, mutual funds with 4.05%, foreign institutional investors (FIIs) at 10.97%, and individual investors holding 24.43%. The highest public shareholder is Pivotal Enterprises Private Limited with 2.25%.

The top shareholders of Shilpa Medicare include the promoters, who are the majority shareholders. The promoter with the highest holding is Vishnukant Chaturbhuj Bhutada, owning 6.51% of the company. Additionally, mutual funds hold 4.05% through 8 schemes, while foreign institutional investors (FIIs) collectively own 10.97% through 99 FIIs. The highest public shareholder is Pivotal Enterprises Private Limited, which holds 2.25%. Individual investors account for 24.43% of the holdings.

How big is Shilpa Medicare?

As of 24th July, Shilpa Medicare Ltd has a market capitalization of 9,034.00 Cr, with net sales of 1,286.41 Cr and a net profit of 78.29 Cr over the last four quarters. Shareholder's funds are 1,808.69 Cr, and total assets amount to 3,082.94 Cr as of March 2024.

As of 24th July, <BR><BR>Market Cap: Shilpa Medicare Ltd has a market capitalization of 9,034.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1,286.41 Cr, while the sum of Net Profit for the same period is 78.29 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period for the latest annual data is March 2024. Shareholder's Funds stand at 1,808.69 Cr, and Total Assets amount to 3,082.94 Cr.

When is the next results date for Shilpa Medicare?

The next results date for Shilpa Medicare is 13 August 2025.

The next results date for Shilpa Medicare is scheduled for 13 August 2025.

What is the bonus history of Shilpa Medicare?

Shilpa Medicare's most recent bonus issue was a 1:1 bonus announced on October 3, 2025. Previously, the company issued a 1:2 bonus on July 16, 2013.

Shilpa Medicare has a notable bonus history. The most recent bonus issue was a 1:1 bonus announced with an ex-date of October 3, 2025. Prior to that, the company issued a 1:2 bonus on July 16, 2013, with a record date of July 18, 2013. This reflects the company's commitment to rewarding its shareholders through bonus shares over the years.

Is Shilpa Medicare technically bullish or bearish?

As of November 18, 2025, Shilpa Medicare's technical trend has shifted to bearish, indicated by a bearish MACD, Bollinger Bands, and moving averages, despite a mildly bullish signal from Dow Theory on the weekly chart.

As of 18 November 2025, the technical trend for Shilpa Medicare has changed from mildly bearish to bearish. The current technical stance is bearish with moderate strength. Key indicators driving this stance include a bearish MACD on the weekly chart, bearish Bollinger Bands, and bearish moving averages on the daily timeframe. The KST is also bearish on the weekly chart, while the Dow Theory shows a mildly bullish signal on the weekly but is mildly bearish on the monthly. Overall, the combination of these indicators suggests a prevailing bearish sentiment in the market.

How has been the historical performance of Shilpa Medicare?

Shilpa Medicare has shown significant growth in net sales, increasing from 1,050.11 Cr in March 2023 to 1,286.41 Cr in March 2025, with improved operating profit and profitability metrics. The company's total assets and shareholder's funds have also risen, indicating a stronger financial position despite a slight decline in cash flow from operating activities.

Answer:<BR>The historical performance of Shilpa Medicare shows a significant increase in net sales, reaching 1,286.41 Cr in March 2025, up from 1,151.60 Cr in March 2024 and 1,050.11 Cr in March 2023. The total operating income mirrored this growth, with a rise to 1,286.41 Cr in March 2025. However, total expenditure also increased to 969.51 Cr in March 2025, compared to 907.11 Cr in March 2024. Operating profit (PBDIT) saw a substantial rise to 340.20 Cr in March 2025 from 252.66 Cr in March 2024, indicating improved operational efficiency. Profit before tax improved to 123.60 Cr in March 2025, up from 59.11 Cr in March 2024, while profit after tax also rose to 79.57 Cr from 36.74 Cr. The earnings per share increased to 4.0 in March 2025, compared to 3.67 in March 2024. <BR><BR>On the balance sheet side, total assets grew to 3,297.74 Cr in March 2025 from 3,082.98 Cr in March 2024, with total liabilities also increasing to 3,297.74 Cr. Shareholder's funds rose to 2,372.24 Cr in March 2025 from 1,808.69 Cr in March 2024, reflecting a stronger equity position. Cash flow from operating activities was 132.00 Cr in March 2025, slightly down from 136.00 Cr in March 2024, while cash flow from investing activities showed a negative trend at -198.00 Cr. The net cash outflow was -3.00 Cr in March 2025, indicating a slight decrease in cash reserves, which stood at 28.00 Cr at the end of March 2025.<BR><BR>Breakdown:<BR>Shilpa Medicare's financial performance over the years has demonstrated a consistent upward trend in net sales, which increased from 733.39 Cr in March 2019 to 1,286.41 Cr in March 2025. This growth in revenue has been accompanied by fluctuations in operating profit, which peaked at 340.20 Cr in March 2025, showcasing improved operational efficiency despite rising expenditures. The profit before tax also reflected a positive trajectory, moving from a loss of -34.47 Cr in March 2023 to a profit of 123.60 Cr in March 2025. The company's earnings per share have rebounded from a negative figure in March 2023 to 4.0 in March 2025, indicating a recovery in profitability. On the balance sheet, total assets and shareholder's funds have both increased significantly, highlighting a strengthening financial position, while cash flow from operating activities remained stable despite a slight decline. Overall, Shilpa Medicare's financial metrics indicate a robust recovery and growth trajectory in recent years.

Is Shilpa Medicare overvalued or undervalued?

As of December 2, 2025, Shilpa Medicare's stock is considered attractive due to its undervaluation, highlighted by a PE ratio of 40.69 and a PEG ratio of 0.21, despite recent underperformance against the Sensex.

As of 2 December 2025, Shilpa Medicare's valuation grade has moved from fair to attractive, indicating a more favorable assessment of its stock. The company appears to be undervalued, especially when considering its key ratios: a PE ratio of 40.69, an EV to EBITDA of 20.27, and a PEG ratio of 0.21, which suggests strong growth potential relative to its price. <BR><BR>In comparison to its peers, Shilpa Medicare's valuation stands out; for instance, Sun Pharma has a PE ratio of 37.36 and an EV to EBITDA of 24.69, while Cipla shows a PE of 22.57 and an EV to EBITDA of 15.96, both of which are lower than Shilpa's ratios. Despite recent underperformance against the Sensex, with a year-to-date return of -16.11% compared to the Sensex's 8.96%, the attractive valuation suggests that Shilpa Medicare may present a compelling investment opportunity moving forward.

Are Shilpa Medicare Ltd latest results good or bad?

Shilpa Medicare Ltd's latest Q3 FY26 results show strong revenue and profit growth, with record revenue of ₹409.73 crore and a net profit increase of 40.28%. However, concerns about low return on equity (6.73%) and underperformance in the stock market suggest a cautious investment outlook.

Shilpa Medicare Ltd's latest results for Q3 FY26 present a mixed picture. On one hand, the company achieved a record revenue of ₹409.73 crore, reflecting a significant year-on-year growth of 28.32% and a quarter-on-quarter increase of 10.75%. Additionally, the net profit rose to ₹44.58 crore, marking a robust year-on-year growth of 40.28%. The operating margin also improved to 27.90%, the highest in the last eight quarters, indicating effective cost management.<BR><BR>However, there are notable concerns. The return on equity (ROE) remains low at 6.73%, which is below industry standards, raising questions about the company’s ability to generate adequate returns for shareholders. Furthermore, the stock has underperformed the market, with a negative return of 14.69% over the past year compared to the Sensex's positive return of 7.07%. <BR><BR>The technical outlook for the stock is also concerning, as it is currently trading below all key moving averages, indicating a mildly bearish trend. While the quarterly results show strong operational performance, the underlying issues related to capital efficiency and market skepticism suggest that investors should approach with caution. <BR><BR>In summary, while the latest results show strong revenue and profit growth, the persistent weaknesses in capital efficiency and stock performance indicate a more cautious investment outlook.

Which are the latest news on Shilpa Medicare?

Should I buy, sell or hold Shilpa Medicare Ltd?

Why is Shilpa Medicare Ltd falling/rising?

As of 06-May, Shilpa Medicare Ltd's stock price is rising to Rs 442.10, up 4.17%, driven by strong performance metrics and increased investor interest. The stock has outperformed the Sensex significantly over various time frames, indicating robust momentum and positive financial results.

As of 06-May, Shilpa Medicare Ltd's stock price is rising, currently at Rs 442.10, reflecting an increase of Rs 17.7 or 4.17%. This upward movement is supported by several key factors. Over the past week, the stock has gained 9.38%, significantly outperforming the Sensex, which only rose by 0.60%. In the last month, the stock has increased by 13.03%, while the benchmark index rose by 5.20%. Year-to-date, Shilpa Medicare has shown remarkable growth of 37.64%, contrasting with the Sensex's decline of 8.52%.<BR><BR>Today's performance highlights that the stock has outperformed its sector by 1.5% and has been on a consecutive gain streak for the last four days, accumulating a total return of 9.1% during this period. The stock reached an intraday high of Rs 448.7, marking a 5.73% increase at its peak. Additionally, Shilpa Medicare is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating strong momentum.<BR><BR>Investor participation has also increased, with delivery volume on May 5 rising by 255.05% compared to the 5-day average, suggesting heightened interest in the stock. The broader Pharmaceuticals & Drugs sector has gained by 2.41%, contributing to the positive sentiment surrounding Shilpa Medicare.<BR><BR>The company's financial performance further supports the stock's rise, with a reported growth in net sales of 10.75% and positive results declared for the last ten consecutive quarters. The return on capital employed (ROCE) is at its highest level of 8.57%, and the operating profit to interest ratio is also strong at 10.70 times. These factors, combined with consistent returns over the past three years, reinforce the stock's upward trajectory.